Item 1.01 | Entry into a Material Definitive Agreement. |
Underwriting Agreement
On February 12, 2025, SailPoint, Inc. (the “Company”) and certain existing stockholders of the Company (the “Selling Stockholders”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the initial public offering (the “IPO”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”). The Underwriting Agreement provides for the offer and sale by the Company of 57,500,000 shares of Common Stock (the “Company Shares”) and the offer and sale by the Selling Stockholders of 2,500,000 shares of Common Stock (the “Selling Stockholder Shares” and, together with the Company Shares, the “Firm Shares”), in each case at a public offering price of $23.00 per share. Pursuant to the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to an additional 9,000,000 shares of Common Stock (the “Option Shares”). The purchase price payable by the Underwriters for the Firm Shares and any Option Shares is $21.9075 per share.
The Underwriting Agreement contains customary representations and warranties, agreements and obligations, closing conditions and termination provisions. The Company and the Selling Stockholders have agreed to indemnify the Underwriters against (or contribute to the payment of) certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”).
On February 14, 2025, the IPO closed and the Firm Shares were delivered. The material terms of the IPO are described in the prospectus, dated February 12, 2025 (the “Prospectus”), filed by the Company with the Securities and Exchange Commission (the “Commission”) on February 14, 2025, pursuant to Rule 424(b) under the Securities Act. The IPO is registered with the Commission pursuant to the Company’s Registration Statement on Form S-1, as amended (File No. 333-284339).
The foregoing summary description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the copy of the Underwriting Agreement attached hereto as Exhibit 1.1, which is incorporated by reference into this Item 1.01. In addition, for a summary description of relationships between the Company and the Underwriters, see the “Underwriting” section in the Prospectus.
Director Designation Agreement
In connection with the IPO, on February 12, 2025, the Company entered into a Director Designation Agreement with certain stockholders (the “Director Designation Agreement”). A summary description of the Director Designation Agreement is contained in the Prospectus under the section titled “Certain Relationships and Related Party Transactions—Related Party Transactions—Director Designation Agreement” and is incorporated herein by reference. Such summary description does not purport to be complete and is qualified in its entirety by reference to the copy of the Director Designation Agreement attached hereto as Exhibit 10.1, which is incorporated by reference into this Item 1.01. In addition, for a summary description of material relationships between the Company and the stockholders party to the Director Designation Agreement, see the section titled “Certain Relationships and Related Party Transactions—Related Party Transactions” in the Prospectus, which is incorporated herein by reference.
Item 3.03 | Material Modifications to Rights of Security Holders. |
The information provided under Item 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On or around February 12, 2025, in connection with the IPO, the Company entered into indemnification agreements with each of its directors and executive officers. These agreements provide the Company’s directors and executive officers with contractual rights to indemnification, expense advancement and reimbursement, to the fullest extent permitted under the Delaware General Corporation Law. These indemnification rights are not